Advanced Breast Cancer Clinical Trials in Shanghai
8 recruitingShanghai, China
Showing 1–8 of 8 trials
Recruiting
Phase 3
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca500 enrolled296 locationsNCT06380751
Recruiting
Dalpiciclib in HR+/HER2- ABC
Advanced Breast Cancer
RenJi Hospital103 enrolled1 locationNCT06301438
Recruiting
Early Phase 1
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
Breast CancerAdvanced Breast CancerTreatment Side Effects+1 more
Shanghai Juncell Therapeutics50 enrolled1 locationNCT05142475
Recruiting
Phase 2
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
Advanced Breast Cancer
Wenjin Yin123 enrolled1 locationNCT07180160
Recruiting
Trastuzumab Deruxtecan in Advanced Breast Cancer
Advanced Breast Cancer
Wenjin Yin118 enrolled1 locationNCT07180264
Recruiting
Phase 2
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Advanced Breast Cancer
Wenjin Yin186 enrolled1 locationNCT07180082
Recruiting
Not Applicable
RC48-ADC in HER2-low Advanced Breast Cancer
Advanced Breast Cancer
RenJi Hospital36 enrolled1 locationNCT05831878
Recruiting
Not Applicable
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
Advanced Breast Cancer
Wenjin Yin86 enrolled1 locationNCT05876065